The Life Science Feed
Deep dives with clinicians, researchers, and industry leaders.
All episodes
Genetic Test Identifies Breast Cancer Patients Who May Avoid Chemotherapy
A genetic test can identify patients with early-stage, hormone receptor-positive, HER2-negative breast cancer who may safely forgo adjuvant chemotherapy.
Solid TumorsWearable Devices Detect CAR-T CRS Hours Earlier, Improving Patient Outcomes
Wearable devices identify cytokine release syndrome (CRS) in CAR-T cell therapy recipients hours before clinical recognition, enabling earlier intervention and potentially reducing severe complications.
Prostatic NeoplasmsAlpha-Emitting Radioantibody Lowers PSA in CRPC
An investigational alpha-emitting radioantibody demonstrated a reduction in PSA levels in patients with castration-resistant prostate cancer (CRPC).
Giredestrant Improves Breast Cancer Survival Regardless of Menopause
8 min readProstate Care: Balancing Immediate Relief with Long-Term Retreatment
10 min readTucatinib Extends PFS in HER2-Positive Breast Cancer, No New Safety Signals
11 min readBiomarkers and Novel Treatments Highlight Prostate Cancer Advances at ASCO
9 min readHalf of Older Adults With Metastatic Lung Cancer Receive No Systemic Treatment
8 min read
Hypotension Linked to Increased Alzheimer's Disease Risk
New research indicates that mid-life hypotension is a significant cardiovascular risk factor for later-life Alzheimer's disease, challenging prior assumptions.
Heart FailureUniversal Heart Failure Definition Issued by Global Societies
Four major cardiology societies released a universal definition of heart failure, aiming to standardise diagnosis and research across the globe.
CardiomyopathiesESC Cardio-Oncology 2026: Key Sessions and Anticipated Focus Areas
The ESC Cardio-Oncology 2026 congress will address cardiotoxicity from cancer therapies, focusing on early detection and management strategies.
Lipoprotein(a) Risk: Define, Test Early, Optimise Management
7 min readNovel Therapies Target Atherogenic Lp(a) Particle
11 min readHeat-Attributable CVD Years of Life Lost Projected to Rise Through 2050
8 min readClopidogrel and Omeprazole: Re-evaluating Concomitant Use Risk
7 min readAI-Assisted Fetal Echocardiography Improves Early CHD Detection
8 min read
Omnipod 5 Improves CGM Metrics, Reduces Hypoglycaemia in Diabetes
A real-world study of the Omnipod 5 automated insulin delivery system showed improvements in time in range and reduced hypoglycaemia.
Diabetes Mellitus Type 2GLP-1 Receptor Agonist Use Varies Widely for Youth Type 2 Diabetes
Geographic variation in GLP-1 receptor agonist prescribing for youths with type 2 diabetes across the US highlights disparities in care.
Diabetes Mellitus Type 2Elecoglipron Oral GLP-1 Reduces Glucose, Weight in Phase 2
Elecoglipron, an investigational oral GLP-1 receptor agonist, demonstrated reductions in HbA1c and body weight in phase 2 trials.
Bariatric Surgery: Efficacy and Emerging Pharmacotherapies in Obesity Management
12 min readFoundayo Confers Greater HbA1c Reduction Than Farxiga, Ozempic Pill in T2D
8 min readGLP-1 Nonresponders Often Underserved by Inadequate Dosing, Poor Adherence
10 min readMedically Tailored Meals Cut HbA1c More Than Subsidies in Type 2 Diabetes
11 min readIsaacs Emphasizes 'Human Touch' in Diabetes Care Beyond Technology
Migraine Linked to Increased Vascular Dementia Odds in Observational Data
Observational studies indicate a consistent association between a history of migraine and elevated odds for developing vascular dementia later in life.
Parkinson DiseaseBrief Brain Stimulation Effective for Depression in Parkinson's Disease
Magnetic seizure therapy (MST) demonstrated non-inferiority to ultra-brief electroconvulsive therapy (ECT) for depression, with fewer cognitive adverse effects.
Alzheimer DiseaseGlucosamine/Chondroitin Tied to Faster AD Progression
A recent analysis indicates that regular use of glucosamine and chondroitin may accelerate Alzheimer's disease progression in susceptible individuals.
GLP-1s do not improve migraines, but reduce healthcare utilisation
7 min readFast Five Quiz: Assessment of Tardive Dyskinesia
7 min readEptinezumab Improves Cognitive Symptoms in Migraine Patients
13 min readHuntington's Disease Therapy Faces Regulatory Setbacks, Clinical Impact
10 min readDopamine Agonists: A Fading Role in Parkinson's Treatment?
9 min readVitamin K2 Supplementation May Curb Coronary Calcification
12 min readNew Parkinson's Drug Offers Sustained Levodopa Levels
Munich, DEAug 28 – 31UpcomingEASD 2026
Madrid, ESSep 9 – 12UpcomingERS 2026
Copenhagen, DKSep 12 – 15UpcomingESMO 2026Berlin, DESep 12 – 16UpcomingECTRIMS 2026Barcelona, ESSep 17 – 20UpcomingUEG Week 2026
Vienna, ATOct 3 – 7UpcomingAHA 2026
Chicago, USNov 7 – 9UpcomingACR 2026Washington DC, USNov 14 – 19UpcomingASH 2026New Orleans, USDec 12 – 15UpcomingACC.27 Together With WCCHouston, USApr 10 – 12PastENDO 2026Boston, USJun 13 – 16PastEHA 2026
Stockholm, SEJun 11 – 14PastEULAR 2026
London, GBJun 3 – 6PastASCO 2026Chicago, USMay 29 – Jun 2PastEASL 2026Barcelona, ESMay 27 – 30UpcomingESC 2026Munich, DEAug 28 – 31UpcomingEASD 2026Madrid, ESSep 9 – 12UpcomingERS 2026Copenhagen, DKSep 12 – 15UpcomingESMO 2026Berlin, DESep 12 – 16UpcomingECTRIMS 2026Barcelona, ESSep 17 – 20UpcomingUEG Week 2026Vienna, ATOct 3 – 7UpcomingAHA 2026Chicago, USNov 7 – 9UpcomingACR 2026Washington DC, USNov 14 – 19UpcomingASH 2026New Orleans, USDec 12 – 15UpcomingACC.27 Together With WCCHouston, USApr 10 – 12PastENDO 2026Boston, USJun 13 – 16PastEHA 2026Stockholm, SEJun 11 – 14PastEULAR 2026London, GBJun 3 – 6PastASCO 2026Chicago, USMay 29 – Jun 2PastEASL 2026Barcelona, ESMay 27 – 30
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
A novel liver-directed treatment presented at endo 2026 offers a targeted approach for metabolic dysfunction, addressing a significant unmet clinical need.
Liver CirrhosisEASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
EASL 2026 will feature a Skills Learning Centre on liver and spleen elastography, highlighting its role in non-invasive fibrosis assessment.
Hepatocellular CarcinomaEASL Congress 2026: Key Trials to Watch in Liver Disease Management
EASL Congress 2026 will feature pivotal trials in NAFLD/NASH, HBV, and HCC, potentially reshaping current treatment paradigms.
Metabolic Dysfunction Associated Steatotic Liver Disease: An Overview
5 min readAlcohol and Sugar: A Dual Metabolic Challenge for Patients
7 min readA-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis
8 min readEASL 2026 Forum: Enhancing Patient-Clinician Communication
8 min readVariceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
New Regimen Confers 'Meaningful' Benefit in Aggressive Lymphoma
7 min readFDA Expands Casgevy for Sickle Cell in Children 2 Years and Older
8 min readMonoclonal Antibodies May Complicate Transfusion Testing
7 min readBlood Transfusion Safety: Pathogen Inactivation Reduces Transfusion-Transmitted Infections
7 min readChemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
8 min readPersonalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
7 min readMacrophages: Dual Role in Haematological Malignancies Explored
7 min readMolecular Hematology: From Gene Profiles to Therapy Profiles at EHA 2026
7 min readITP Management: Bridging Clinician and Patient Perspectives
7 min readCLL: Aligning Patient Priorities with Targeted Therapy at EHA 2026
8 min read
Sleep Disruption and Fear Drive Chronic Rheumatic Pain
11 min readPodcast: Why Cheaper Humira Alternatives Face Resistance
ListenPodcast: Stopping Spinal Fusion Or Protecting The Gut?
ListenPodcast: Chasing Absolute Zero In Rheumatoid Arthritis
ListenPodcast: The ORAL Surveillance JAK Inhibitor Controversy
Listen
Air Embolism: Two Cases After Percutaneous Lung Biopsy
7 min readSingle Question May Flag Poor Quality Sleep in Patients
9 min readPembrolizumab Reduces Pulmonary AEs vs Chemotherapy in NSCLC
8 min readDupilumab Superior to Omalizumab in High-Biomarker Asthma
7 min readATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
8 min read
COVID Vaccine Efficacy in Children: A Review of Real-World Data
8 min readRifadin Syrup Under Review for Carcinogen Concerns
7 min readPublic Health Measures Significantly Reduced COVID-19 Incidence
8 min readData Integrity Concerns Raised in Pfizer's COVID-19 Vaccine Trial
7 min readVaccine Cold Chain Integrity Underpins Vaccine Security
8 min read
Prior Authorization Delays Atopic Dermatitis Treatment Access
13 min readPatient-Reported Factors Redefine Alopecia Areata Severity
7 min readScalp Lesions: Rare Malignancies Mimic Benign Conditions
7 min readDown Syndrome: Skin Conditions Demand Dermatologists’ Attention
7 min readGLP-1 Receptor Agonists and Psoriatic Disease: A Deep Dive
7 min readBRINSUPRI® First Therapy Approved for NCFB at ATS 2026
7 min readCurrent and Emerging Therapies for Pulmonary Tuberculosis
6 min readGoat Milk Formula Linked With Less Atopic Dermatitis
7 min read
HER2-Expressing Breast Cancer: Advancements in Targeted Therapies
CLL First-Line Treatment: BTK Inhibitors vs. Venetoclax Combinations
EULAR 2026: Polymyalgia Rheumatica Guidelines Incorporate RWE
MASH Advanced Fibrosis: Experts Detail Unique Challenges at EASL 2026
BTK Inhibitors in CLL: Evolving Landscape and Sequential Strategies
Multimodal OSA Treatment: Nerve Stimulation, Surgery, Oral Appliances
MCED Tests Show Promise for Earlier Cancer Detection at ASCO 2026
Desiccated Thyroid Extract: Efficacy and Safety in Hypothyroidism
Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps
Low Alkaline Phosphatase: Recognizing Clinical Consequences
Acromegaly Management: Focus on Biochemical Control at ENDO 2026
Optimising PsA and axSpA Treatment: EULAR 2026 Focuses on Early Intervention
ASCO 2026 May 30th Program Highlights: Immunotherapy Advances in Solid Tumors
IKT-001 Adaptive Study Programme for Pulmonary Arterial Hypertension
Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue
MASH Diagnosis: Non-Invasive Markers Show Promise at EASL 2026
MASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines
More Breast Cancer Patients Can Skip Axillary Dissection
XLH Adults: Osteomalacia Persists Despite Conventional Therapy
CAR T-Cell Therapy Guidelines Evolve for Lymphoma, Myeloma at EHA 2026
Afirma Molecular Testing: Unique Situations and New Prognostic Development
Cancer Elimination at ASCO 2026: Aspirational Goals and Current Realities
Multidisciplinary Care Improves Spondyloarthritis Outcomes
MLVs: Dual Role in Brain Metastases Offers Therapeutic Targets
Tafasitamab-R-CHOP Boosts Frontline DLBCL Outcomes at ASCO 2026
DLBCL Treatment Sequencing: EHA 2026 Explores Current Therapies
Macrophages: Dual Role in Haematological Malignancies Explored
FLT3mut+ AML Outcomes: EHA 2026 Reviews Current Strategies
BCMA Bispecifics Transition to Community Myeloma Care: EHA 2026
AI Foundation Models Enhance Diagnostic Insights in Oncology
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
Ventilator Management: Foundations for Bedside Implementation
NDMM Treatment Advances: Quadruplet Regimens Show Efficacy
EASL Congress 2026: Key Trials to Watch in Liver Disease Management
ILD Diagnosis and Management: A Practical ATS 2026 Update
IDH1m AML: Ivosidenib Plus Azacitidine Improves OS by 12.5 Months
Tirzepatide: Efficacy in Weight Management Explored at ATS 2026
DNA Methylation Patterns Emerge as Sarcoma Biomarkers
EULAR 2026: Earlier AxSpA Recognition Improves Disease Burden
Chemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
CLL First-Line Therapy: Case-Based Insights from EHA 2026
Tile Radiation for Large Brain Mets: A New Approach at ASCO 2026
EASL 2026: PSC Therapies Advance Beyond Symptom Management
Bispecific Antibodies Efficacious in Multiple Myeloma with Renal Impairment
Late-Onset Genetic Cholestasis: Underdiagnosis in Adults Examined
CAR T: Speed and Reliability Critical for Patient Outcomes
Eosinophilic Disorders: Best Practices for HES and EGPA at ATS 2026
Autoantibodies: Hidden Drivers of Autoimmune Rheumatic Diseases
Bispecific Antibodies Show Promise in Relapsed/Refractory Multiple Myeloma
Caplacizumab Improves iTTP Outcomes in Real-World Settings
CPET Advances Refine Cardiopulmonary Disease Assessment at ATS 2026
Pediatric Pulmonary Research Gaps Highlighted for Global Health
ICI Dissemination Challenges Highlighted at ASCO 2026
Treat-to-Target in SLE: Balancing Burden, Benefit, and Risk
Iron Status Clarifies Erythrocytosis, Symptoms in Polycythemia Vera
Doctor-Patient Communication Improves Treatment Acceptance in Cancer
AML: Fitness, Not Age, Predicts IC Eligibility at EHA 2026
Personalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
Rare Conditions: EHA 2026 Highlights Diagnostic Challenges
Novel Therapies Improve Outcomes Post-cBTKi in CLL at EHA 2026
Bispecific Antibodies Positioned in Relapsed Follicular Lymphoma
Severe Asthma: Beyond Airway Focus in Treatment Decisions at ATS 2026
Next-Gen Extracellular Vesicles: Biomarkers, Targets, Deliverables in Oncology
EULAR 2026: Psoriatic Disease Spectrum Highlights
Multidisciplinary Approach Improves Autoimmune ILD Management
CD19+ B-Cell Targeting Shows Efficacy in IgG4-RD Management
EASL 2026 Forum: Enhancing Patient-Clinician Communication
ANCA Vasculitis: Evolving Strategies Target Remission & Relapse Prevention
HYRNUO® (Sevabertinib) Shows Efficacy in Advanced Solid Tumours
Multiple Myeloma: Aligning Innovation with Clinical Practice at EHA 2026
Lupus Management: Progress and Persistent Challenges at EULAR 2026
XLH Management: Rheumatology Must Adapt at EULAR 2026
Outsmarting Shape-Shifting Lung Cancer Resistance
Early SLE Disease Control: Targeting IFN Pathway at EULAR 2026
Early AxSpA Diagnosis: Case-Based Discussion at EULAR 2026
AML Treatment Strategies: Optimising Outcomes in a Complex Disease
Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome
Avapritinib Improves Outcomes in Nonadvanced and Advanced Systemic Mastocytosis
DLBCL Treatment: Emerging Targeted Therapies at EHA 2026
Korlym® Improves Cushing's Syndrome Symptoms in Patient Experience Data
Systemic Sclerosis: EULAR 2026 Highlights Diagnosis, Prognosis
SpA Remission: Clinical Symptoms vs. Subclinical Inflammation at EULAR 2026
EULAR 2026: Methotrexate Remains Cornerstone in RA First-Line
Radiopharmaceutical Therapy: Improving Effectiveness, Access, and Safety
Early ILD Recognition in SARD/SSc: Drivers of Progression and Workflow Solutions
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
Rapid SLE Control Prevents Organ Damage: EULAR 2026 Focus
NDMM Treatment Optimisation: Communication Key to Individualisation
YUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients
CAR T Therapy Shows Sustained Efficacy in Relapsed/Refractory Lymphoma
Myelofibrosis Management: Cytopenia Guides Treatment at EHA 2026
Subcutaneous Immunotherapy Offers Alternative Administration at ASCO 2026
Endocrinologists' Role in Early Thyroid Eye Disease Recognition
ATS 2026: Addressing the Cough Assessment Gap in Respiratory Disease
Early Intervention Crucial for Inflammatory Joint Disease, Osteoporosis
IPF/PPF: Patient and Pulmonologist Perspectives Highlight Care Gaps
AI, Wearables Transform Sleep Diagnostics: ATS 2026 Preview
Acute Respiratory Failure: Lifespan Phenotypes and Trajectories
PEAK Study Shows Novel Agent Improves PFS in Advanced GIST
Novel Approaches in R/R MM: Expert Perspectives from EHA 2026
ATS 2026: Ultrasound Education Advances for Clinical Practice
IL-33's Dual Role in COPD: Inflammation and Mucus Dysfunction
Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
Triple Therapy in Asthma: Real-World Evidence Supports Earlier Use
AI in Hematology: EHA 2026 Focuses on Practical, Ethical Integration
12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis
Classic CAH: New Approaches to Glucocorticoid Dosing
Biomarkers and Novel Treatments Highlight Prostate Cancer Advances at ASCO
Defining Hyperphagia Treatment Possibilities in Prader-Willi Syndrome
TRUQAP + Fulvestrant: 2L Option for HR+/HER2- aBC/mBC with PI3K-AKT Alterations
Novel Approaches Address Multiple Myeloma Resistance at EHA 2026
CLL: Aligning Patient Priorities with Targeted Therapy at EHA 2026
Molecular Hematology: From Gene Profiles to Therapy Profiles at EHA 2026
Contagion: Acute Respiratory Failure Cases Highlight Ventilator Management
Pediatric Advanced Bronchoscopy: Precision in Airway Management
DLBCL Management: Bispecific Antibodies as Emerging Therapeutic Option
CD38 mAb Quad Therapy: Subcutaneous Dosing Reduces Burden
FLT3 Inhibitors Improve AML Outcomes Pre- and Post-Transplant
How Immunotherapy Unmasks Invisible Lung Cancer
EGPA: Early Recognition & Targeted Intervention Improve Outcomes
EASL 2026 Consensus: AATD-Liver Disease Management Standardised
CELMoDs Show Promise in Relapsed/Refractory Multiple Myeloma
RA Care: Navigating Treatment Choices at EULAR 2026
ASCO 2026 May 29th Program Highlights: Novel Oncology Therapies
Cancer Care Disparities Highlighted in Crisis, Displaced Populations
Belantamab Mafodotin's Evolving Role in RRMM: EHA 2026 Insights
Early Breast Cancer at ASCO 2026: Trials to Watch
SLE Pathophysiology Advances Inform Future Precision Care at EULAR 2026
BRINSUPRI® First Therapy Approved for NCFB at ATS 2026
Symptom Science Integration Improves Cancer Outcomes at ASCO 2026
TACE + Camrelizumab/Rivoceranib Improves OS in Unresectable HCC
Fixed-Duration BCL-2 Combo Offers Time Off Treatment in 1L CLL
Real-World Data Confirms Proximal Complement Inhibition in PNH
Peer Insights on Once-Daily Weight Management Therapy at endo 2026
EHA 2026: Anticipating Advances in Haematological Malignancies
CAR T Cell Therapy Shows Efficacy in Autoimmune Diseases at EULAR 2026
Early Intervention in SLE/LN Reduces Long-Term Damage
Desmopressin Dosing Refined for Central Diabetes Insipidus
VEXAS Syndrome: Expert Consensus on Multidisciplinary Care at EULAR 2026
Epithelial Dysfunction: A Unified Target in Airway Disease Management
DLBCL Relapse: EHA 2026 Addresses Gaps in Treatment Strategy
AATD: Aiming for AAT Restoration and Clinically Meaningful Endpoints
TLR7/8 Inhibition Offers New Lupus Perspective at EULAR 2026
Immuno-Fibrotic Crosstalk: A New Target in Rheumatology
NK Cell Immunotherapy: Biology to Clinic at AACR 2026
Inluriyo™ and Verzenio® Presentations at ASCO 2026
ASCO 2026 May 31st Program Highlights: Focus on Novel Immunotherapies
Sarcoidosis: Current Understanding of Diagnosis and Management
Immunological Insights Inform ILD & Transplant Outcomes
Immunotherapy and Targeted Therapy: New Data from ASCO 2026
Triple Therapy Optimises COPD Outcomes at ATS 2026
MAVEs Inform Variant Interpretation in Clinical Oncology Practice
BCMA-Directed Therapies Show Efficacy in Relapsed/Refractory Multiple Myeloma
JASCAYD® (nerandomilast) Offers New Therapeutic Option for COPD
New Biologic Offers Option for Severe Eosinophilic Asthma
A-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis
RA Patients Face Elevated Fracture Risk: EULAR 2026 Highlights
AIRSUPRA® Reduces Asthma Exacerbations in ATS 2026 Data
Cancer Therapies Induce Lifespan Comorbidities: ACCR 2026 Review
RA Treatment Optimisation: Applying Two Decades of Progress
Sjögren’s Disease: Targeting Underlying Activity Beyond Symptoms
Infection Prevention Critical in Hematological Malignancies
MRD Status Guides First-Line Treatment Duration in Haematologic Malignancies
Novel Biomarkers Improve Pediatric Solid Tumor Detection
Salivary Galectin-9 Elevated in Primary Sjögren's, Lacks Disease Activity Correlation
EASL 2026: Alcohol Policy Action Needed for Liver Disease
Few Pediatric Cancer Drugs Reach Phase 3 or Approval
HTAN Decodes Tumor Evolution: Ecological Perspective at AACR2026
Bronchoscopy Training: ATS 2026 Focuses on EBUS and Guided Techniques
Obesity Care: Tailored Treatment Strategies Highlighted at endo 2026
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
GLP-1 RAs Reduce CV Risk in T2D Via Weight, Glucose Pathways
Inflammation Drives Sickle Cell Disease Pathophysiology
ASCO 2026 June 1st Program Highlights: Novel Immunotherapy Data
Infection Prevention Critical in Hematological Malignancies
ATS 2026: Lung Cancer Management Advances in Targeted Therapy
AAT Protein's Role in Lung Health Beyond COPD & Severe Asthma
AML: Rethinking Intensive Therapy for Myelodysplasia-Related & Therapy-Related Subtypes
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
JAK Inhibitor Combinations Show Efficacy in Myelofibrosis at EHA 2026
ITP Management: Bridging Clinician and Patient Perspectives
AI Algorithms Enhance Pulmonary Disease Management at ATS 2026
Bispecific Antibodies in FL: EHA 2026 Explores Advancing Outcomes
AML: Fitness, Not Age, Predicts Intensive Chemotherapy Eligibility
Obesity Management Improves Psoriatic Disease Outcomes
Right Heart Catheterization: ATS 2026 Clarifies Waveform Interpretation
CAR T Cell Therapy Shows Promise in SLE and SSc Immune Reset
Evolving Infection Prevention in HSCT and Cellular Therapies
HDV Management: EASL 2026 Highlights PegIFN-α as Standard
EASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging
Hypercortisolism: Emerging Diagnostic and Management Insights
Immune Drivers in Autoimmune Cytopenias Inform Patient Care
CLL: EHA 2026 to Address Unmet Needs in Treatment Selection
CAR T in DLBCL: Optimising Patient Outcomes at EHA 2026
AI in Oncology: Practical Applications Transforming Cancer Care
Oncodetect® MRD Test Shows Analytical Validity, Clinical Utility at ASCO
Optimising Transplant in Haemoglobinopathies: EHA 2026 Perspectives
Hypothyroidism: Symptom Burden Persists Despite Euthyroidism
ATS 2026: Bronchiectasis and NTM Pulmonary Disease Management
Yoga Reduces Insomnia, Fatigue, Anxiety in Cancer Survivors
Myriad's Precise MRD™ Test Shows Ultra-Sensitive Detection at ASCO 2026
B-Cell Dysregulation Targeted Upstream in Primary Sjögren Disease
Optimizing Frontline LR-MDS Treatment: EHA 2026 Data Review
ASCO 2026: Anticipating Advances in Oncology Treatment
AI Integration Improves Lung Cancer MDT Workflow at ATS 2026
ATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
New 2L+ Combination Therapy Shows Efficacy in RRMM Post-PI/IMiD
CD20-Targeted Therapies Remain Central to NHL Management
CML Survivorship: Beyond Survival to Quality of Life
Bispecific Antibodies Show Promise in Relapsed/Refractory Haematological Malignancies
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
Epithelial Cytokines Link Severe Asthma, CRSwNP, COPD at ATS 2026
HER2-Expressing Breast Cancer: Advancements in Targeted Therapies
CLL First-Line Treatment: BTK Inhibitors vs. Venetoclax Combinations
EULAR 2026: Polymyalgia Rheumatica Guidelines Incorporate RWE
MASH Advanced Fibrosis: Experts Detail Unique Challenges at EASL 2026
BTK Inhibitors in CLL: Evolving Landscape and Sequential Strategies
Multimodal OSA Treatment: Nerve Stimulation, Surgery, Oral Appliances
MCED Tests Show Promise for Earlier Cancer Detection at ASCO 2026
Desiccated Thyroid Extract: Efficacy and Safety in Hypothyroidism
Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps
Low Alkaline Phosphatase: Recognizing Clinical Consequences
Acromegaly Management: Focus on Biochemical Control at ENDO 2026
Optimising PsA and axSpA Treatment: EULAR 2026 Focuses on Early Intervention
ASCO 2026 May 30th Program Highlights: Immunotherapy Advances in Solid Tumors
IKT-001 Adaptive Study Programme for Pulmonary Arterial Hypertension
Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue
MASH Diagnosis: Non-Invasive Markers Show Promise at EASL 2026
MASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines
More Breast Cancer Patients Can Skip Axillary Dissection
XLH Adults: Osteomalacia Persists Despite Conventional Therapy
CAR T-Cell Therapy Guidelines Evolve for Lymphoma, Myeloma at EHA 2026
Afirma Molecular Testing: Unique Situations and New Prognostic Development
Cancer Elimination at ASCO 2026: Aspirational Goals and Current Realities
Multidisciplinary Care Improves Spondyloarthritis Outcomes
MLVs: Dual Role in Brain Metastases Offers Therapeutic Targets
Tafasitamab-R-CHOP Boosts Frontline DLBCL Outcomes at ASCO 2026
DLBCL Treatment Sequencing: EHA 2026 Explores Current Therapies
Macrophages: Dual Role in Haematological Malignancies Explored
FLT3mut+ AML Outcomes: EHA 2026 Reviews Current Strategies
BCMA Bispecifics Transition to Community Myeloma Care: EHA 2026
AI Foundation Models Enhance Diagnostic Insights in Oncology
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
Ventilator Management: Foundations for Bedside Implementation
NDMM Treatment Advances: Quadruplet Regimens Show Efficacy
EASL Congress 2026: Key Trials to Watch in Liver Disease Management
ILD Diagnosis and Management: A Practical ATS 2026 Update
IDH1m AML: Ivosidenib Plus Azacitidine Improves OS by 12.5 Months
Tirzepatide: Efficacy in Weight Management Explored at ATS 2026
DNA Methylation Patterns Emerge as Sarcoma Biomarkers
EULAR 2026: Earlier AxSpA Recognition Improves Disease Burden
Chemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
CLL First-Line Therapy: Case-Based Insights from EHA 2026
Tile Radiation for Large Brain Mets: A New Approach at ASCO 2026
EASL 2026: PSC Therapies Advance Beyond Symptom Management
Bispecific Antibodies Efficacious in Multiple Myeloma with Renal Impairment
Late-Onset Genetic Cholestasis: Underdiagnosis in Adults Examined
CAR T: Speed and Reliability Critical for Patient Outcomes
Eosinophilic Disorders: Best Practices for HES and EGPA at ATS 2026
Autoantibodies: Hidden Drivers of Autoimmune Rheumatic Diseases
Bispecific Antibodies Show Promise in Relapsed/Refractory Multiple Myeloma
Caplacizumab Improves iTTP Outcomes in Real-World Settings
CPET Advances Refine Cardiopulmonary Disease Assessment at ATS 2026
Pediatric Pulmonary Research Gaps Highlighted for Global Health
ICI Dissemination Challenges Highlighted at ASCO 2026
Treat-to-Target in SLE: Balancing Burden, Benefit, and Risk
Iron Status Clarifies Erythrocytosis, Symptoms in Polycythemia Vera
Doctor-Patient Communication Improves Treatment Acceptance in Cancer
AML: Fitness, Not Age, Predicts IC Eligibility at EHA 2026
Personalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
Rare Conditions: EHA 2026 Highlights Diagnostic Challenges
Novel Therapies Improve Outcomes Post-cBTKi in CLL at EHA 2026
Bispecific Antibodies Positioned in Relapsed Follicular Lymphoma
Severe Asthma: Beyond Airway Focus in Treatment Decisions at ATS 2026
Next-Gen Extracellular Vesicles: Biomarkers, Targets, Deliverables in Oncology
EULAR 2026: Psoriatic Disease Spectrum Highlights
Multidisciplinary Approach Improves Autoimmune ILD Management
CD19+ B-Cell Targeting Shows Efficacy in IgG4-RD Management
EASL 2026 Forum: Enhancing Patient-Clinician Communication
ANCA Vasculitis: Evolving Strategies Target Remission & Relapse Prevention
HYRNUO® (Sevabertinib) Shows Efficacy in Advanced Solid Tumours
Multiple Myeloma: Aligning Innovation with Clinical Practice at EHA 2026
Lupus Management: Progress and Persistent Challenges at EULAR 2026
XLH Management: Rheumatology Must Adapt at EULAR 2026
Outsmarting Shape-Shifting Lung Cancer Resistance
Early SLE Disease Control: Targeting IFN Pathway at EULAR 2026
Early AxSpA Diagnosis: Case-Based Discussion at EULAR 2026
AML Treatment Strategies: Optimising Outcomes in a Complex Disease
Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome
Avapritinib Improves Outcomes in Nonadvanced and Advanced Systemic Mastocytosis
DLBCL Treatment: Emerging Targeted Therapies at EHA 2026
Korlym® Improves Cushing's Syndrome Symptoms in Patient Experience Data
Systemic Sclerosis: EULAR 2026 Highlights Diagnosis, Prognosis
SpA Remission: Clinical Symptoms vs. Subclinical Inflammation at EULAR 2026
EULAR 2026: Methotrexate Remains Cornerstone in RA First-Line
Radiopharmaceutical Therapy: Improving Effectiveness, Access, and Safety
Early ILD Recognition in SARD/SSc: Drivers of Progression and Workflow Solutions
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
Rapid SLE Control Prevents Organ Damage: EULAR 2026 Focus
NDMM Treatment Optimisation: Communication Key to Individualisation
YUTREPIA® (treprostinil) Inhalation Powder for PH-ILD Patients
CAR T Therapy Shows Sustained Efficacy in Relapsed/Refractory Lymphoma
Myelofibrosis Management: Cytopenia Guides Treatment at EHA 2026
Subcutaneous Immunotherapy Offers Alternative Administration at ASCO 2026
Endocrinologists' Role in Early Thyroid Eye Disease Recognition
ATS 2026: Addressing the Cough Assessment Gap in Respiratory Disease
Early Intervention Crucial for Inflammatory Joint Disease, Osteoporosis
IPF/PPF: Patient and Pulmonologist Perspectives Highlight Care Gaps
AI, Wearables Transform Sleep Diagnostics: ATS 2026 Preview
Acute Respiratory Failure: Lifespan Phenotypes and Trajectories
PEAK Study Shows Novel Agent Improves PFS in Advanced GIST
Novel Approaches in R/R MM: Expert Perspectives from EHA 2026
ATS 2026: Ultrasound Education Advances for Clinical Practice
IL-33's Dual Role in COPD: Inflammation and Mucus Dysfunction
Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
Triple Therapy in Asthma: Real-World Evidence Supports Earlier Use
AI in Hematology: EHA 2026 Focuses on Practical, Ethical Integration
12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis
Classic CAH: New Approaches to Glucocorticoid Dosing
Biomarkers and Novel Treatments Highlight Prostate Cancer Advances at ASCO
Defining Hyperphagia Treatment Possibilities in Prader-Willi Syndrome
TRUQAP + Fulvestrant: 2L Option for HR+/HER2- aBC/mBC with PI3K-AKT Alterations
Novel Approaches Address Multiple Myeloma Resistance at EHA 2026
CLL: Aligning Patient Priorities with Targeted Therapy at EHA 2026
Molecular Hematology: From Gene Profiles to Therapy Profiles at EHA 2026
Contagion: Acute Respiratory Failure Cases Highlight Ventilator Management
Pediatric Advanced Bronchoscopy: Precision in Airway Management
DLBCL Management: Bispecific Antibodies as Emerging Therapeutic Option
CD38 mAb Quad Therapy: Subcutaneous Dosing Reduces Burden
FLT3 Inhibitors Improve AML Outcomes Pre- and Post-Transplant
How Immunotherapy Unmasks Invisible Lung Cancer
EGPA: Early Recognition & Targeted Intervention Improve Outcomes
EASL 2026 Consensus: AATD-Liver Disease Management Standardised
CELMoDs Show Promise in Relapsed/Refractory Multiple Myeloma
RA Care: Navigating Treatment Choices at EULAR 2026
ASCO 2026 May 29th Program Highlights: Novel Oncology Therapies
Cancer Care Disparities Highlighted in Crisis, Displaced Populations
Belantamab Mafodotin's Evolving Role in RRMM: EHA 2026 Insights
Early Breast Cancer at ASCO 2026: Trials to Watch
SLE Pathophysiology Advances Inform Future Precision Care at EULAR 2026
BRINSUPRI® First Therapy Approved for NCFB at ATS 2026
Symptom Science Integration Improves Cancer Outcomes at ASCO 2026
TACE + Camrelizumab/Rivoceranib Improves OS in Unresectable HCC
Fixed-Duration BCL-2 Combo Offers Time Off Treatment in 1L CLL
Real-World Data Confirms Proximal Complement Inhibition in PNH
Peer Insights on Once-Daily Weight Management Therapy at endo 2026
EHA 2026: Anticipating Advances in Haematological Malignancies
CAR T Cell Therapy Shows Efficacy in Autoimmune Diseases at EULAR 2026
Early Intervention in SLE/LN Reduces Long-Term Damage
Desmopressin Dosing Refined for Central Diabetes Insipidus
VEXAS Syndrome: Expert Consensus on Multidisciplinary Care at EULAR 2026
Epithelial Dysfunction: A Unified Target in Airway Disease Management
DLBCL Relapse: EHA 2026 Addresses Gaps in Treatment Strategy
AATD: Aiming for AAT Restoration and Clinically Meaningful Endpoints
TLR7/8 Inhibition Offers New Lupus Perspective at EULAR 2026
Immuno-Fibrotic Crosstalk: A New Target in Rheumatology
NK Cell Immunotherapy: Biology to Clinic at AACR 2026
Inluriyo™ and Verzenio® Presentations at ASCO 2026
ASCO 2026 May 31st Program Highlights: Focus on Novel Immunotherapies
Sarcoidosis: Current Understanding of Diagnosis and Management
Immunological Insights Inform ILD & Transplant Outcomes
Immunotherapy and Targeted Therapy: New Data from ASCO 2026
Triple Therapy Optimises COPD Outcomes at ATS 2026
MAVEs Inform Variant Interpretation in Clinical Oncology Practice
BCMA-Directed Therapies Show Efficacy in Relapsed/Refractory Multiple Myeloma
JASCAYD® (nerandomilast) Offers New Therapeutic Option for COPD
New Biologic Offers Option for Severe Eosinophilic Asthma
A-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis
RA Patients Face Elevated Fracture Risk: EULAR 2026 Highlights
AIRSUPRA® Reduces Asthma Exacerbations in ATS 2026 Data
Cancer Therapies Induce Lifespan Comorbidities: ACCR 2026 Review
RA Treatment Optimisation: Applying Two Decades of Progress
Sjögren’s Disease: Targeting Underlying Activity Beyond Symptoms
Infection Prevention Critical in Hematological Malignancies
MRD Status Guides First-Line Treatment Duration in Haematologic Malignancies
Novel Biomarkers Improve Pediatric Solid Tumor Detection
Salivary Galectin-9 Elevated in Primary Sjögren's, Lacks Disease Activity Correlation
EASL 2026: Alcohol Policy Action Needed for Liver Disease
Few Pediatric Cancer Drugs Reach Phase 3 or Approval
HTAN Decodes Tumor Evolution: Ecological Perspective at AACR2026
Bronchoscopy Training: ATS 2026 Focuses on EBUS and Guided Techniques
Obesity Care: Tailored Treatment Strategies Highlighted at endo 2026
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
GLP-1 RAs Reduce CV Risk in T2D Via Weight, Glucose Pathways
Inflammation Drives Sickle Cell Disease Pathophysiology
ASCO 2026 June 1st Program Highlights: Novel Immunotherapy Data
Infection Prevention Critical in Hematological Malignancies
ATS 2026: Lung Cancer Management Advances in Targeted Therapy
AAT Protein's Role in Lung Health Beyond COPD & Severe Asthma
AML: Rethinking Intensive Therapy for Myelodysplasia-Related & Therapy-Related Subtypes
Allogeneic Cell Therapy for EBV+ PTLD: EHA 2026 Insights
JAK Inhibitor Combinations Show Efficacy in Myelofibrosis at EHA 2026
ITP Management: Bridging Clinician and Patient Perspectives
AI Algorithms Enhance Pulmonary Disease Management at ATS 2026
Bispecific Antibodies in FL: EHA 2026 Explores Advancing Outcomes
AML: Fitness, Not Age, Predicts Intensive Chemotherapy Eligibility
Obesity Management Improves Psoriatic Disease Outcomes
Right Heart Catheterization: ATS 2026 Clarifies Waveform Interpretation
CAR T Cell Therapy Shows Promise in SLE and SSc Immune Reset
Evolving Infection Prevention in HSCT and Cellular Therapies
HDV Management: EASL 2026 Highlights PegIFN-α as Standard
EASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging
Hypercortisolism: Emerging Diagnostic and Management Insights
Immune Drivers in Autoimmune Cytopenias Inform Patient Care
CLL: EHA 2026 to Address Unmet Needs in Treatment Selection
CAR T in DLBCL: Optimising Patient Outcomes at EHA 2026
AI in Oncology: Practical Applications Transforming Cancer Care
Oncodetect® MRD Test Shows Analytical Validity, Clinical Utility at ASCO
Optimising Transplant in Haemoglobinopathies: EHA 2026 Perspectives
Hypothyroidism: Symptom Burden Persists Despite Euthyroidism
ATS 2026: Bronchiectasis and NTM Pulmonary Disease Management
Yoga Reduces Insomnia, Fatigue, Anxiety in Cancer Survivors
Myriad's Precise MRD™ Test Shows Ultra-Sensitive Detection at ASCO 2026
B-Cell Dysregulation Targeted Upstream in Primary Sjögren Disease
Optimizing Frontline LR-MDS Treatment: EHA 2026 Data Review
ASCO 2026: Anticipating Advances in Oncology Treatment
AI Integration Improves Lung Cancer MDT Workflow at ATS 2026
ATS 2026: NTM Lung Disease Detection, Therapy, QoL Advancements
New 2L+ Combination Therapy Shows Efficacy in RRMM Post-PI/IMiD
CD20-Targeted Therapies Remain Central to NHL Management
CML Survivorship: Beyond Survival to Quality of Life
Bispecific Antibodies Show Promise in Relapsed/Refractory Haematological Malignancies
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
Epithelial Cytokines Link Severe Asthma, CRSwNP, COPD at ATS 2026
